Canada not recommending AstraZeneca's (AZN) Lynparza for reimbursement - Bloomberg

October 5, 2016 8:15 AM EDT
Get Alerts AZN Hot Sheet
Trade AZN Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

AstraZeneca (NYSE: AZN) says Canada not recommending Lynparza for reimbursement, according to Bloomberg.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Trader Talk

Add Your Comment